These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral. Mendez R; Abboud H; Burdick J; Copley B; Freeman R; Batiuk TD; Cooney GF; Barbeito R Clin Ther; 1999 Jan; 21(1):160-71. PubMed ID: 10090433 [TBL] [Abstract][Full Text] [Related]
3. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Canadian Neoral Renal Transplantation Study Group Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic analysis of Neoral conversion in pediatric and adult renal transplant recipients with poor absorption of Sandimmune. Pescovitz MD; Henson S; Bodziak K; Book BK; Gonin J; Jindal RM; Leapman SB; Milgrom ML; Filo RS Transplant Proc; 1996 Aug; 28(4):2165-8. PubMed ID: 8769189 [No Abstract] [Full Text] [Related]
5. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. International Neoral Renal Transplantation Study Group. Am J Transplant; 2002 Feb; 2(2):148-56. PubMed ID: 12099517 [TBL] [Abstract][Full Text] [Related]
6. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients. van Mourik ID; Thomson M; Kelly DA Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349 [TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of equoral versus neoral in stable renal transplant patients: a multinational multicenter study. Masri MA; Haberal M; Rizvi A; Stephan A; Bilgin N; Naqvi A; Barbari A; Kamel G; Zafar N; Emiroğlu R; Colak T; Manzoor K; Matha V; Kamarad V; Rizk S; Itany AR; Shehedeh I Transplant Proc; 2004; 36(1):80-3. PubMed ID: 15013306 [TBL] [Abstract][Full Text] [Related]
17. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group. Keown P; Niese D Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620 [TBL] [Abstract][Full Text] [Related]
18. Convenience of level of cyclosporine-Neoral at time 3 to determine the area under curve in renal transplant. Rial MC; Frias S; Argento J; Tessler J; Casadei D Transplant Proc; 1997; 29(1-2):292-3. PubMed ID: 9123001 [No Abstract] [Full Text] [Related]
19. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation]. Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]